Company Profile

Cassava Sciences (AKA: Pain Therapeutics Inc)
Profile last edited on: 2/17/2023      CAGE: 49XX9      UEI: ZENEXUHPHMJ3

Business Identifier: Drugs for neurodegenerative diseases such as Alzheimers
Year Founded
1998
First Award
2004
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7801 North Capital Of Texas Highway Suite 260
Austin, TX 78731
   (512) 501-2444
   cwaarich@paintrials.com
   www.paintrials.com
Location: Single
Congr. District: 10
County: Travis

Public Profile

In March 2019, PainTherapeutics (NASDAQ:PTIE) announced that, effective immediately - better to reflect the shift in medical focus - the firm would be known as Cassava Sciences Inc (NASDAQ:SAVA). Previously located in California, Cassava Sciences is a biopharmaceutical company developing novel drugs originally based on technology licensed from the Albert Einstein College of Medicine: the firm having exclusive worldwide rights to patents covering low-dose opioid antagonist technology. With in-licensing over the years of technologies from others, the company?'s current lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. The firm also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat Alzheimer?s disease and other neurological disorders. The company is currently in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that does not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. Cassava Scences is also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : SAVA
IP Holdings
25-49

Awards Distribution by Agency

Key People / Management

  Remi Barbier -- President

  Lindsay H Burns

  Nadav Friedmann -- Chief Medical and Operating Officer

  Shawn Kucera

  Grant L Schoenhard -- Chief Scientific Officer

  George B Thornton

  Mike S Zamloot

Company News

There are no news available.